The chief of the U.S. Food and Drug Administration (FDA), Dr. Marty Makary, is stepping down following a tumultuous tenure marked by criticisms from various sectors close to U.S. President Donald Trump. Makary’s resignation was announced on Tuesday, just over a year after assuming leadership of the influential regulatory body.
A respected surgeon and health expert, Makary gained attention within Republican circles for his vocal opposition to COVID-19 health protocols during the pandemic, frequently appearing on Fox News Channel. However, he faced challenges in navigating the FDA’s complex bureaucracy and failed to earn the trust of its staff following significant layoffs, leadership changes, and instances where political interests seemed to override scientific principles, including those of Health Secretary Robert F. Kennedy Jr.
President Trump acknowledged Makary’s departure, noting his struggles while expressing confidence in his future endeavors. Trump confirmed Kyle Diamantas, the agency’s food chief, as the expected acting commissioner. Diamantas, an attorney with personal connections to Donald Trump Jr., is set to assume the interim leadership role.
Makary’s role as FDA commissioner involved balancing scientific considerations and political pressures, overseeing regulations on a wide range of consumer products and medications. He grappled with conflicting demands to streamline FDA processes from Trump and Republicans while addressing Kennedy’s concerns about vaccine, drug, and food safety.
Significant turnover in senior FDA officials during the early stages of the Trump administration’s second term contributed to a climate of internal discontent, with leaks and negative reports highlighting staff morale issues. Makary’s chosen deputy, Dr. Vinay Prasad, faced challenges and ultimately left the agency multiple times due to conflicts with pharmaceutical companies and patient advocacy groups.
Recent criticisms from influential interest groups, such as anti-abortion organizations and vaping industry representatives, further complicated Makary’s position. Anti-abortion advocates accused him of delaying a review of the abortion pill mifepristone, while vaping executives alleged obstruction in product approvals. Despite recent policy changes accommodating fruit-flavored e-cigarettes, Makary’s resignation was imminent.
To fill the vacant FDA commissioner role permanently, President Trump will nominate a candidate for Senate confirmation. Makary’s tenure was marked by efforts to expedite drug reviews and incorporate innovative approaches, though internal disputes and inconsistent decision-making processes strained relationships with pharmaceutical stakeholders.
Controversial decisions on vaccine eligibility and internal conflicts within the FDA, particularly regarding COVID-19 vaccine approvals, underscored the challenges faced by Makary and his team. Prasad’s actions, including rejecting vaccine recommendations and proposing sweeping changes, met resistance from former FDA commissioners and raised concerns about the agency’s vaccine approval process.